Alzheimer’s Disease/Dementia News

Brigham and Women’s Hospital will soon commence a clinical trial to test the first nasally administered treatment intended to arrest the progression of Alzheimer’s disease, according to a press release.

A blood test may be able to identify individuals at increased risk for developing Alzheimer’s disease symptoms, according to research presented at the Clinical Trials on Alzheimer’s Disease conference.

The American Academy of Neurology has issued ethical guidance on Aduhelm that outlines important points for neurologists to communicate to patients eligible for the treatment.

The Alzheimer's Association and collaborators announced the formation of a national database, the National Treatment and Diagnostic Alzheimer’s Registry, at the Clinical Trials on Alzheimer’s Disease conference.

Drinking multiple cups of coffee or tea a day, or a combination of the two, was associated with a decreased risk for dementia and stroke, according to findings published in PLOS Medicine.

Additional contingency reserves related to uncertainty surrounding the potential use of Aduhelm by individuals with Medicare contributed to projected increases in the 2022 Medicare Part B premium and deductible, according to CMS.

Daily low-dose aspirin use over 7 years did not affect the risk for incident dementia or cognitive decline in U.K. adults with type 2 diabetes, according to new data from the ASCEND trial.

Daily low-dose aspirin use over 7 years did not affect the risk for incident dementia or cognitive decline in U.K. adults with type 2 diabetes, according to new data from the ASCEND trial.

Patients with alopecia areata had increased risk for dementia, according to a nationwide cohort study published in Journal of Clinical Psychiatry.

Reproductive history events indicating more estrogen exposure correlated with larger gray matter volume in midlife women, according to a study published in Neurology.